X-ray Structural Studies of Retinal Dystrophies

视网膜营养不良的 X 射线结构研究

基本信息

项目摘要

DESCRIPTION (provided by applicant): My goal is to investigate the structural basis of retinal and neurological disorders using x-ray crystallography. In order to become an independent investigator in the field of structural biology, I propose to undertake a course of training with preeminent x-ray crystallographer, Wayne A. Hendrickson, Department of Biochemistry and Molecular Biophysics, Columbia University. The specific aims of this proposal concern the structural determination of three proteins that are related to retinal dystrophies: alpha-tocopherol transfer protein (ATTP), cellular retinaldehyde binding protein (CRALBP), and rhodopsin. Mutations in the gene encoding ATTP have been shown to cause a late onset retinal dystrophy and ataxia with isolated vitamin E deficiency, an autosomal recessive condition characterized by a progressive spinocerebellar degeneration. Mutations in CRALBP have been shown to cause a number of autosomal recessive retinal dystrophies. Finally, mutations in rhodopsin have been shown to cause autosomal dominant retinitis pigmentosa (ADRP) and congenital stationary night blindness. ATTP and CRALBP are both cytosolic proteins that bind insoluble hydrophobic small molecules, and regulate their availability to the whole body (for vitamin E) or the photoreceptor (for 11-cis-retinal). The structures of these proteins should help to elucidate the function of this class of proteins. Rhodopsin is a G protein coupled receptor (GPCR), perhaps the most important class of receptor molecules. Although a high resolution structure of ground-state rhodopsin was recently reported, the structure of the activated form of rhodopsin is still unknown. My aim is to determine the structure of activated rhodopsin in a complex with transducin, its cognate G protein. Such a structure would have ramifications for the entire GPCR family, as well as disease causing mutations of rhodopsin. Specific Aim 1 is expression and purification of CRALBP and ATTP. Specific Aim 2 is crystallization and structure determination of CRALBP and ATTP. Specific Aim 3 is crystallization and structural determination of native bovine rhodopsin. Specific Aim 4 is crystallization and structure determination of activated bovine rhodopsin alone or with transducin. Specific Aim 5 is development of an expression system for rhodopsin suitable for use in Specific Aim 4 and 5, with mutants of rhodopsin as an alternative strategy to pursue the structure of the active state of rhodopsin. Specific Aim 6 is the use of the systems described in Aims 3, 4, and 5, to analyze the mechanism of signal transduction by rhodopsin using mutants and x-ray structure determination.
描述(由申请人提供):我的目标是使用X射线结晶学研究视网膜和神经疾病的结构基础。为了成为结构生物学领域的一名独立研究员,我建议参加哥伦比亚大学生物化学和分子生物物理系杰出的X射线结晶学家韦恩·A·亨德里克森的培训课程。这项建议的具体目标涉及与视网膜营养不良相关的三种蛋白质的结构测定:α-生育酚转移蛋白(ATTP)、细胞视黄醛结合蛋白(CRALBP)和视紫红质。编码ATTP的基因突变已被证明会导致迟发性视网膜营养不良和共济失调,并伴有孤立的维生素E缺乏,这是一种以进行性脊髓小脑变性为特征的常染色体隐性疾病。CRALBP基因突变已被证明可导致一系列常染色体隐性遗传性视网膜营养不良。最后,视紫红质突变已被证明可导致常染色体显性遗传性视网膜色素变性(ADRP)和先天性静止性夜盲。ATTP和CRALBP都是胞质蛋白,它们结合不溶的疏水小分子,调节它们对全身(维生素E)或光感受器(11-顺式视网膜)的利用。这些蛋白质的结构应该有助于阐明这类蛋白质的功能。视紫红质是一种G蛋白偶联受体,可能是最重要的一类受体分子。尽管最近报道了基态视紫红质的高分辨结构,但激活形式的视紫红质的结构仍不清楚。我的目标是确定转导蛋白与其同源G蛋白的复合体中激活的视紫红质的结构。这样的结构将对整个GPCR家族产生影响,以及导致视紫红质突变的疾病。特异靶1:CRALBP和ATTP的表达和纯化。具体目标2为CRALBP和ATTP的结晶和结构测定。具体目标3:天然牛视紫红质的结晶和结构测定。特异靶4:活化牛视紫质单独或与转导蛋白的结晶和结构测定。具体目的5是开发一种适用于特定目的4和5的视紫红质表达系统,视紫红质突变体作为寻找视紫红质活性状态结构的替代策略。具体目标6是使用目标3、4和5中描述的系统,利用突变体和X射线结构测定来分析视紫红质的信号转导机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kwan-Hong Christopher Min其他文献

Kwan-Hong Christopher Min的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kwan-Hong Christopher Min', 18)}}的其他基金

CRYSTAL STRUCTURE OF COMPLEX OF CRALBP WITH 11-CIS-RETINAL
CRALBP与11-CIS-视网膜复合物的晶体结构
  • 批准号:
    7726010
  • 财政年份:
    2008
  • 资助金额:
    $ 16.78万
  • 项目类别:
X-ray Structural Studies of Retinal Dystrophies
视网膜营养不良的 X 射线结构研究
  • 批准号:
    7110950
  • 财政年份:
    2004
  • 资助金额:
    $ 16.78万
  • 项目类别:
X-ray Structural Studies of Retinal Dystrophies
视网膜营养不良的 X 射线结构研究
  • 批准号:
    6919175
  • 财政年份:
    2004
  • 资助金额:
    $ 16.78万
  • 项目类别:
X-ray Structural Studies of Retinal Dystrophies
视网膜营养不良的 X 射线结构研究
  • 批准号:
    6769040
  • 财政年份:
    2004
  • 资助金额:
    $ 16.78万
  • 项目类别:
X-ray Structural Studies of Retinal Dystrophies
视网膜营养不良的 X 射线结构研究
  • 批准号:
    7454209
  • 财政年份:
    2004
  • 资助金额:
    $ 16.78万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.78万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了